Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

AstraZeneca has said that it will stop a Phase III trial of its chronic lymphocytic leukaemia drug Calquence (acalabrutinib) early after the drug met its primary endpoint in an interim analysis.

The addition of statin medications to contemporary therapies like ibrutinib could significantly improve survival for patients ...

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says show a safety advantage over Imbruvica ...

The European Commission granted marketing authorization to AstraZeneca’s BTK inhibitor, Calquence, as a combination treatment, for first-line mantle cell lymphoma (MCL), a rare and typically ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated ...

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...